Relay Therapeutics (RLAY) said Wednesday updated interim clinical data from its first-in-human study of RLY-2608 in combination with fulvestrant showed "clinically meaningful" progression-free survival in patients with locally advanced or metastatic breast cancer.
The updated data showed a median progression-free survival of 11.4 months in second-line patients who received a 600-milligram dosage of RLY-2608 twice a day plus fulvestrant, the company said, adding its RLY-2608 and fulvestrant arm enrolled 118 patients, and was "generally well tolerated."
The company plans to start a pivotal study of RLY-2608 plus fulvestrant in 2025, with data from the phase 1/2 study to be released the same year.
Relay Therapeutics shares were up nearly 6% in recent Wednesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。